Back to search results

A Study of Enlicitide and Rosuvastatin in Healthy Adults

This study is looking for healthy adults, aged 18 to 55, to help researchers understand how two medicines, enlicitide and rosuvastatin, work in the body. You cannot smoke or use nicotine products to join. Researchers will compare how much enlicitide and rosuvastatin are in your body over time when given separately versus when combined into one tablet. The main goal is to measure the total amount of each medicine in your body over a period of up to 168 hours (7 days). The study is currently unclear on its recruitment status and plans to enroll about 60 participants.

Study design
This interventional study plans to enroll 60 healthy adult participants. It compares different forms of enlicitide and rosuvastatin.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your body's levels of enlicitide and rosuvastatin will be measured for up to 168 hours (7 days) after you take the medicine.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07300280

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

Recruiting
PHASE1Ages 18–55InterventionalBasic science
Merck Sharp & Dohme LLC
~60 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:MK-0616AEnlicitideRosuvastatin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide
Measured over Pre dose and at designated time points up to 168 hours post dose
+5 more outcomes measured

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
Arizona1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

Toll Free Number
[email protected]
1-888-577-8839
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Is medically healthy with no clinically significant medical history
Is a non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to study entry

Exclusion

Is unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to study entry
Is a female participant of childbearing potential

What this trial measures

  • Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of EnlicitidePre dose and at designated time points up to 168 hours post dose

    Blood samples will be collected to determine the AUC0-inf of enlicitide in plasma

  • AUC0-Inf of RosuvastatinPre dose and at designated time points up to 168 hours post dose

    Blood samples will be collected to determine the AUC0-inf of rosuvastatin in plasma

  • Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of EnlicitdePre dose and at designated time points up to 168 hours post dose

    Blood samples will be collected to determine the AUC0-last of enlicitide in plasma

  • AUC0-Last of RosuvastatinPre dose and at designated time points up to 168 hours post dose

    Blood samples will be collected to determine the AUC0-last of rosuvastatin in plasma

  • Maximum Plasma Concentration (Cmax) of EnlicitidePre dose and at designated time points up to 168 hours post dose

    Blood samples will be collected to determine the cmax of enlicitide in plasma

  • Cmax of RosuvastatinPre dose and at designated time points up to 168 hours post dose

    Blood samples will be collected to determine the cmax of rosuvastatin in plasma